MENU
Anatomy
Anesthesiology
Biochemistry
Biomedical Informatics
Biophysics
Cell Biology
Clinical Cases
Dentistry
Dermatovenerology
Emergency Medicine
Family Medicine
Forensic Medicine
Gynecology and Obstetrics
Histology and Embryology
History of Medicine
Human Genetics
Hygiene
Infectious Diseases
Internal Medicine
Medical Deontology and Philosophy
Medical Psychology
Microbiology and Immunology
Neurology
Occupational Medicine
Oncology
Ophthalmology
Orthopaedics
Otorhinolaryngology
Pathology
Pathophysiology
Pediatrics
Pharmacology and Experimental Toxicology
Physical and Rehabilitation Medicine
Physiology
Psychiatry
Radiology
Social Medicine
Surgery
Toxicology
Research papers
Clinical research paper
Preclinical research paper
Sponsored articles
2017 » 3 » | Archive » Medical field » Fields » Internal Medicine »

Incretin System in Polycystic Ovary Syndrome: A Basis for a New Treatment Strategy in Specific Subgroups of Women with Polycystic Ovary Syndrome with High Metabolic Risk

 
Abstract:

This post is also available in: enEnglish slSlovenščina (Slovenian)

Polycystic ovary syndrome is a common endocrine disorder which affects 15–20% of women in reproductive age. It is characterised by disturbances in the menstrual cycle and hyperandrogenism. These women are more prone to obesity. Regulation of appetite and energy intake is essential to maintain or reduce body mass. This regulation is provided by communication between the central nervous system and gastrointestinal signals, part of which are the incretin hormones. Weight reduction with non-pharmacological methods alone is often ineffective. More effective reduction and subsequent weight maintenance is achieved by coadministration of metformin, which is not well tolerated in 5–10% of patients with polycystic ovary syndrome. Glucagon-like peptide 1 receptor agonists are linked with weight lowering potential in different obesity related populations. Studies using glucagon-like peptide 1 receptor agonists in patients with polycystic ovary syndrome are also promising. Glucagon-like peptide 1 receptor agonists may have a potential role in the treatment of obese patients with polycystic ovary syndrome before a planned pregnancy. Dipeptidyl-peptidase 4 inhibitors promote extended endogenous incretin effect and lead to improvement in metabolic control as well as the reduction of metabolic risks. Because of these effects dipeptidyl-peptidase 4 inhibitors might represent an alternative pharmacological intervention in patients with polycystic ovary syndrome and high metabolic risk when therapy with metformin is contraindicated. Research in this area is currently lacking.

Authors:
Simona Ferjan, Andrej Janež, Mojca Jensterle Sever

Keywords:
polycystic ovary syndrome, body mass, appetite, glucagon-like peptide 1 receptor agonists, dipeptidyl-peptidase 4 inhibitors

Cite as:
Med Razgl. 2017; 56 (4): 373–84.
© 2020 Društvo Medicinski razgledi | Na vrh strani / To top ↑